Proteasome modulation for treatment of corneal disorders
Disclosed herein are methods and compositions useful for preventing or reducing corneal haze of opacification resulting from Limbal Stem Cell Deficiency (LSCD). The invention comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. The invention also comprises a method of preventing or treating corneal opacification, comprising administering to a subject a sufficient amount of a proteasome modulator. In addition, the invention comprises a method of administering to a subject suffering from corneal opacification with a sufficient amount of proteasome modulator, resulting in reduction of Keratin proteins in the cornea of the subject.
1. A method of treating diseased corneal epithelium caused by Limbal Stem Cell Deficiency (LSCD) and characterized with keratin aggregation in a subject, comprising administering to the subject an effective amount of PS-341 (Bortezomib).
2. The method of claim 1 , wherein the PS-341 is formulated as an ophthalmic preparation.
3. The method of claim 2 , wherein the PS-341 is administered once every 72 hours.
4. The method of claim 2 , wherein the PS-341 is administered once every 48 hours.
5. The method of claim 2 , wherein the PS-341 is administered once every 24 hours.
6. A method for reducing keratin aggregation in the cornea caused by Limbal Stem Cell Deficiency (LSCD) in a subject in need thereof, comprising administering to the subject an effective amount of PS-341 (Bortezomib).
7. A method of treating diseased corneal epithelium caused by Limbal Stem Cell Deficiency (LSCD) and characterized with keratin aggregation in the cornea in a subject comprising administering to the subject an effective amount of PS-341 formulated as an ophthalmic preparation and administered every 24 to 72 hours, wherein the method results in reduced levels of Keratin proteins in the cornea of the subject as compared to before the administration.